Icatibant: HOE 140, JE 049, JE049

Drugs in R and D

Volumn 6, Issue 4, 2005, Pages 239-244

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

B 7418; BRADYKININ B2 RECEPTOR ANTAGONIST; CANDESARTAN; DEXTRO ARGINYLBRADYKININ[3 HYDROXYPROLINE 5,8 [3 (2 THIENYL)ALANINE] 7 DEXTRO PHENYLALANINE]; DEXTRO ARGINYLBRADYKININ[3 HYDROXYPROLINE 7 DEXTRO PHENYLALANINE]; ICATIBANT; QUINAPRIL; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANGIONEUROTIC EDEMA; ASCITES; ASIA; ASTHMA; AUSTRALIA; BURN; CANADA; CHEMICAL MODIFICATION; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; EUROPE; FOOD AND DRUG ADMINISTRATION; GUINEA PIG; HEALTH SERVICE; HEART ARRHYTHMIA; HUMAN; LIVER CIRRHOSIS; MARKETING; NONHUMAN; NORTH AMERICA; PANCREATITIS; PERENNIAL RHINITIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; REFRACTORY PERIOD; REGISTRATION; REVIEW; RHINITIS; SKIN IRRITATION; SOUTH AMERICA; STATISTICAL SIGNIFICANCE; TRACHEA;

ANIMALS; BRADYKININ; CARDIOVASCULAR AGENTS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; RECEPTOR, BRADYKININ B2;

EID: 22244492003     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200506040-00008     Document Type: Review

References (29)

1. Profiles of participating companies. BIO 2004: Annual International Convention. Business Forum: 6 Jun 2004
2. Jerini AG. Jerini Initiates Pivotal Registration Study for Icati-bant in Hereditary Angioedema. Media Release: 8 Sep 2004. Available from URL: http://www.jerini.com
3. Jerini. Company overview. 3rd Annual BioPartnering North America: [2 pages], 6 Feb 2005. Available from URL: http://www.techvision.com
4. Jerini AG. Jerini Receives FDA Fast Track Designation for Icatibant in Hereditary Angioedema. Media Release: 22 Jul 2004. Available from URL: http://www.jerini.com
5. Jerini. Jerini Has Been Granted Orphan Drug Designation by U.S. FDA for Icatibant, JE049, to Treat Patients with Angioedema. Media Release: 18 Nov 2003. Available from URL: http://www.jerini.com
6. Proud D. Clinical application of kinin antagonists. Canadian Journal of Physiology and Pharmacology 72 (Suppl. 2): 19, 1994
7. Jerini. Jerini Announces Positive Results in a Subcutaneous Bioavailability Study for Icatibant. Media Release: 14 Apr 2004. Available from URL: http://www.jerini.com
8. Wirth KJ, Gehring D, Schölkens BA. Effect of Hoe 140 on bradykinin-induced bronchoconstriction in anesthetized guinea pigs. American Review of Respiratory Disease 148: 702-706, Sep 1993
9. Wirth KJ, Gehring D, Schölkens BA. Effect of HOE 140 on bradykinin-induced bronchoconstriction in anaesthetised guinea pigs. Naunyn-Schmiedeberg's Archives of Pharmacology 344 (Suppl. 2): R141, 1991
10. Jerini. Jerini's Bradykinin Antagonist Icatibant Shows Promise in Treatment of Refractory Ascites in Liver Cirrhosis in a Phase II Study. Media Release: 2 Dec 2003. Available from URL: http://www.jerini.com
11. Rosenkranz B, Bork K, Frank J. et al. Proof-of-concept study of icatibant (JE 049), a bradykinin B2 receptor antagonist in treatment of hereditary angioedema. Clinical Pharmacology and Therapeutics 77: 14, No. 2, Feb 2005
12. Jerini AG. Jerini Concludes its Icatibant Phase II Study in Hereditary Angioedema with Positive Results. Media Release: 26 Aug 2004. Available from URL: http://www.jerini.com
13. Sun W, Wainwright CL. The potential antiarrhythmic effects of exogenous and endogenous bradykinin in the ischaemic rat heart in vivo. Coronary Artery Disease 5: 541-550, Jun 1994
14. Gaudron P, Hu K, Zdrojewski T, et al. AT1-receptorblocker versus angiotensin converting enzyme inhibitor in acute myocardial infarction? Role of dosage and bradykinin on remodelling, hemodynamics and mortality in the rat model. Journal of the American College of Cardiology 31 (Suppl. 2A): 311, Feb 1998
15. 2 kinin receptor and can be inhibited by the selective antagonist Hoe 140. Journal of Pharmacology and Experimental Therapeutics 264: 1124-1131, Mar 1993
16. Hock FJ, Wirth K, Albus U. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. British Journal of Pharmacology 102: 769-773, Mar 1991
17. 2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D- Tic7,Oic8]bradykinin). European Journal of Pharmacology 210: 115-120, 14 Jan 1992
18. Félétou M, Germain M, Thurieau C. Agonistic and antagonistic properties of the bradykinin B2 receptor antagonist, Hoe 140, in isolated blood vessels from different species. British Journal of Pharmacology 112: 683-689, Jun 1994
19. Sakamoto T, Sun J, Barnes PJ, et al. Effect of a bradykinin receptor antagonist, HOE 140, against bradykinin- and vagal stimulation-induced airway responses in the guinea-pig. European Journal of Pharmacology 251: 137-142, 14 Jan 1994
20. Sakamoto T, Elwood W, Barnes PJ. Evaluation of a bradykinin antagonist (HOE 140) against bradykinin and platelet activating factor induced airway responses in the guinea pig. Thorax 47: 241P, Mar 1992
21. Sakamoto T, Elwood W, Barnes PJ, et al. Effect of Hoe 140, a new bradykinin receptor antagonist, on bradykinin- and platelet-activating factor-induced bronchoconstriction and airway microvascular leakage in guinea pig. European Journal of Pharmacology 213: 367-373, 31 Mar 1992
22. Sakamoto T, Elwood W, Barnes PJ. Effect of a novel bradykinin antagonist (HOE140) against bradykinin, platelet activating factor, sodium metabisulfite and allergen induced airway responses in the guinea pig. American Review of Respiratory Disease 145: A859, Apr 1992
23. Wirth K, Hock FJ, Albus U. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. British Journal of Pharmacology 102: 774-777, Mar 1991
24. Damas J, Remacle-Volon G. Influence of a long-acting bradykinin antagonist, Hoe 140, on some acute inflammatory reactions in the rat. European Journal of Pharmacology 211: 81-86, 28 Jan 1992
25. Featherstone RL, Parry JE, Church MK. The effects of kinin antagonism with HOE 140 on the response of guinea-pigs to allergen. Clinical and Experimental Allergy 23 (Suppl. 1): 32, Feb 1993
26. Austin CE, Foreman JC, Scadding GK. Reduction by Hoe 140, the B2 kinin receptor antagonist, of antigen-induced nasal blockage. British Journal of Pharmacology 111: 969-971, Apr 1994
27. Cockcroft JR, Chowienczyk PJ, Brett SE. Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist. British Journal of Clinical Pharmacology 38: 317-321, Oct 1994
28. Jerini AG. Jerini Announces Positive Phase II Study Results with Icatibant for the Treatment of Hereditary Angioedema. Media Release: 13 Jan 2004. Available from URL: http:// www.jerini.com
29. Avery J, Barber C. A topical bradykinin antagonist first clinical trial of icatibant nasal spray in seasonal allergic rhinitis. Allergy and Clinical Immunology News (Suppl. 2): 415, 1994